72 related articles for article (PubMed ID: 20658725)
21. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study.
García-Sáenz JA; Martín M; Casado A; Pérez-Segura P; Manrique I; Flores L; Macias JA; Cámara JC; Perezagua C; Díaz-Rubio E
Rev Esp Quimioter; 2002 Sep; 15(3):257-63. PubMed ID: 12582429
[TBL] [Abstract][Full Text] [Related]
22. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
23. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
[TBL] [Abstract][Full Text] [Related]
24. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.
Petrioli R; Frediani B; Manganelli A; Barbanti G; De Capua B; De Lauretis A; Salvestrini F; Mondillo S; Francini G
Cancer; 1996 Jan; 77(2):344-51. PubMed ID: 8625244
[TBL] [Abstract][Full Text] [Related]
25. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
[TBL] [Abstract][Full Text] [Related]
26. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
27. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
28. Once-daily gentamicin in infants and children: a prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity.
Best EJ; Gazarian M; Cohn R; Wilkinson M; Palasanthiran P
Pediatr Infect Dis J; 2011 Oct; 30(10):827-32. PubMed ID: 21577177
[TBL] [Abstract][Full Text] [Related]
29. Management of febrile neutropenia in patients receiving chemotherapy for solid tumors: a retrospective study of twenty cases from the radiotherapy centre, Accra, Ghana.
Vanderpuye V; Yarney J; Beecham K
West Afr J Med; 2010; 29(5):303-8. PubMed ID: 21089015
[TBL] [Abstract][Full Text] [Related]
30. Conservative management of acute appendicitis in children with hematologic malignancies during chemotherapy-induced neutropenia.
Wiegering VA; Kellenberger CJ; Bodmer N; Bergstraesser E; Niggli F; Grotzer M; Nadal D; Bourquin JP
J Pediatr Hematol Oncol; 2008 Jun; 30(6):464-7. PubMed ID: 18525466
[TBL] [Abstract][Full Text] [Related]
31. Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides.
Chen KS; Bach A; Shoup A; Winick NJ
Pediatr Blood Cancer; 2013 Nov; 60(11):1772-7. PubMed ID: 23788258
[TBL] [Abstract][Full Text] [Related]
32. Aminoglycosides' dosage in hematological malignancies and febrile neutropenia: extended interval or conventional dosage?
Se CF; Da VR; Pa CC; Gc FT
Per Med; 2023 Jan; 20(1):5-11. PubMed ID: 36317567
[TBL] [Abstract][Full Text] [Related]
33. Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic stem cell transplantation: effect of aminoglycoside therapy.
Cooper BW; Creger RJ; Soegiarso W; Mackay WL; Lazarus HM
Am J Med; 1993 May; 94(5):497-504. PubMed ID: 8098904
[TBL] [Abstract][Full Text] [Related]
34. Is the addition of aminoglycosides to beta-lactams in cancer patients with febrile neutropenia needed?
Contreras V; Sepúlveda S; Heredia A
Medwave; 2016 Feb; 16 Suppl 1():e6379. PubMed ID: 26938974
[TBL] [Abstract][Full Text] [Related]
35. Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients.
van Maarseveen E; Man WH; Proost J; Neef C; Touw D
Int J Clin Pharm; 2015 Apr; 37(2):342-7. PubMed ID: 25616626
[TBL] [Abstract][Full Text] [Related]
36. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin.
Lerner SA; Seligsohn R; Matz GJ
Am J Med; 1977 Jun; 62(6):919-23. PubMed ID: 868906
[TBL] [Abstract][Full Text] [Related]
37. Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Heng MS; Barbon Gauro J; Yaxley A; Thomas J
Eur J Cancer Care (Engl); 2020 Jan; 29(1):e13155. PubMed ID: 31441568
[TBL] [Abstract][Full Text] [Related]
38. A meta-analysis of the target trough concentration of gentamicin and amikacin for reducing the risk of nephrotoxicity.
Yamada T; Fujii S; Shigemi A; Takesue Y
J Infect Chemother; 2021 Feb; 27(2):256-261. PubMed ID: 33077364
[TBL] [Abstract][Full Text] [Related]
39. Assessment of gentamicin 7 mg/kg once daily for pediatric patients with febrile neutropenia: a pilot project.
Newby B; Prevost D; Lotocka-Reysner H
J Oncol Pharm Pract; 2009 Dec; 15(4):211-6. PubMed ID: 19276140
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units.
Oliveira JF; Silva CA; Barbieri CD; Oliveira GM; Zanetta DM; Burdmann EA
Antimicrob Agents Chemother; 2009 Jul; 53(7):2887-91. PubMed ID: 19364846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
